PT4240396T - Utilização de arnm de ifn-lambda, para o tratamento de infeções virais - Google Patents

Utilização de arnm de ifn-lambda, para o tratamento de infeções virais

Info

Publication number: PT4240396T
Authority: PT; Portugal
Prior art keywords: ifn; viral infections; treating viral; lambda mrna; lambda
Prior art date: 2020-11-04

Application number

PT218055093T

Other languages

English (en)

Original Assignee

Ethris Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-11-04

Filing date

2021-11-04

Publication date

2025-03-26

2021-11-04 Application filed by Ethris Gmbh filed Critical Ethris Gmbh

2025-03-26 Publication of PT4240396T publication Critical patent/PT4240396T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Biophysics (AREA)
Otolaryngology (AREA)
Cell Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

PT218055093T 2020-11-04 2021-11-04 Utilização de arnm de ifn-lambda, para o tratamento de infeções virais PT4240396T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP20205674		2020-11-04

Publications (1)

Publication Number	Publication Date
PT4240396T true PT4240396T (pt)	2025-03-26

Family

ID=73059724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT218055093T PT4240396T (pt)	2020-11-04	2021-11-04	Utilização de arnm de ifn-lambda, para o tratamento de infeções virais

Country Status (15)

Country	Link
US (2)	US20240181011A1 (pt)
EP (2)	EP4240396B1 (pt)
JP (1)	JP2023548498A (pt)
KR (1)	KR20230104140A (pt)
CN (2)	CN117729930A (pt)
AU (1)	AU2021375281A1 (pt)
CA (1)	CA3196195A1 (pt)
DK (1)	DK4240396T5 (pt)
ES (1)	ES3018013T3 (pt)
FI (1)	FI4240396T3 (pt)
IL (1)	IL302689B1 (pt)
MX (1)	MX2023005302A (pt)
PL (1)	PL4240396T3 (pt)
PT (1)	PT4240396T (pt)
WO (1)	WO2022096582A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE208369T1 (de)	1997-08-13	2001-11-15	Biontex Lab Gmbh	Neue lipopolyamine, deren darstellung und anwendung
GB0405634D0 (en) *	2004-03-12	2004-04-21	Univ Southampton	Anti-virus therapy for respiratory diseases
JP5172679B2 (ja) *	2005-09-09	2013-03-27	インペリアルイノベーションズリミテッド	呼吸器疾患の治療のためのインターフェロン−λ療法
FR2925491B1 (fr)	2007-12-19	2010-09-03	Oz Biosciences Sas	Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
EP3581197A1 (de)	2009-07-31	2019-12-18	ethris GmbH	Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
US12064484B2 (en)	2013-06-28	2024-08-20	Ethris Gmbh	Compositions for introducing RNA into cells
CN107405412A (zh) *	2014-11-10	2017-11-28	埃泽瑞斯公司	通过递送bmp编码rna诱导骨生成
CN108064176A (zh) *	2015-04-22	2018-05-22	库瑞瓦格股份公司	用于治疗肿瘤疾病的含有rna的组合物
WO2017167910A1 (en)	2016-03-31	2017-10-05	Ethris Gmbh	Novel minimal utr sequences
WO2018160540A1 (en) *	2017-02-28	2018-09-07	Sanofi	Therapeutic rna

2021
- 2021-11-04 EP EP21805509.3A patent/EP4240396B1/en active Active
- 2021-11-04 ES ES21805509T patent/ES3018013T3/es active Active
- 2021-11-04 PT PT218055093T patent/PT4240396T/pt unknown
- 2021-11-04 EP EP24221858.4A patent/EP4553084A3/en active Pending
- 2021-11-04 MX MX2023005302A patent/MX2023005302A/es unknown
- 2021-11-04 CN CN202180074507.XA patent/CN117729930A/zh active Pending
- 2021-11-04 KR KR1020237014249A patent/KR20230104140A/ko not_active Ceased
- 2021-11-04 CN CN202510472800.1A patent/CN120285155A/zh active Pending
- 2021-11-04 CA CA3196195A patent/CA3196195A1/en active Pending
- 2021-11-04 DK DK21805509.3T patent/DK4240396T5/da active
- 2021-11-04 AU AU2021375281A patent/AU2021375281A1/en active Pending
- 2021-11-04 WO PCT/EP2021/080658 patent/WO2022096582A1/en not_active Ceased
- 2021-11-04 PL PL21805509.3T patent/PL4240396T3/pl unknown
- 2021-11-04 US US18/035,249 patent/US20240181011A1/en active Pending
- 2021-11-04 FI FIEP21805509.3T patent/FI4240396T3/fi active
- 2021-11-04 JP JP2023526600A patent/JP2023548498A/ja active Pending
2023
- 2023-05-04 IL IL302689A patent/IL302689B1/en unknown
2025
- 2025-06-24 US US19/248,327 patent/US20250319160A1/en active Pending

Also Published As

Publication number	Publication date
JP2023548498A (ja)	2023-11-17
IL302689B1 (en)	2025-12-01
ES3018013T3 (en)	2025-05-14
CA3196195A1 (en)	2022-05-12
US20240181011A1 (en)	2024-06-06
PL4240396T3 (pl)	2025-04-22
EP4240396A1 (en)	2023-09-13
EP4240396B1 (en)	2025-01-01
DK4240396T5 (da)	2025-04-07
US20250319160A1 (en)	2025-10-16
CN120285155A (zh)	2025-07-11
DK4240396T3 (da)	2025-03-17
EP4553084A3 (en)	2025-11-26
KR20230104140A (ko)	2023-07-07
WO2022096582A1 (en)	2022-05-12
EP4553084A2 (en)	2025-05-14
AU2021375281A1 (en)	2023-06-01
IL302689A (en)	2023-07-01
CN117729930A (zh)	2024-03-19
MX2023005302A (es)	2023-05-25
FI4240396T3 (fi)	2025-03-31

Publication	Publication Date	Title
SI4204421T1 (sl)	2024-07-31	Spojine in postopki za zdravljenje virusnih okužb
PL4157272T3 (pl)	2025-10-20	Remdesiwir do leczenia zakażeń wirusowych
IL315102A (en)	2024-10-01	COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
IL290792A (en)	2022-04-01	Preparations and methods for treating viral infections
IL281277A (en)	2021-04-29	Preparations and methods for treating viral infections
IL277745A (en)	2020-11-30	Use of FUBP1 inhibitors to treat hepatitis B virus infection
ZA202202370B (en)	2022-11-30	Compositions and methods for treating viral infections
PL3972717T3 (pl)	2023-09-04	Obróbka gazu odlotowego z wykańczania mocznika
IL291146A (en)	2022-05-01	Treatment of hidradenitis with jak inhibitors
ZA202212662B (en)	2023-06-28	Use of compounds for treating viral infections
IL302689B1 (en)	2025-12-01	Using ifn-lambda mRNA to treat viral infections
IL281447A (en)	2021-09-30	Methods and compositions for treating viral infections
GB2595513B (en)	2023-03-29	Treatment of infections
GB201907493D0 (en)	2019-07-10	Agents and methods for treating viral infections
IL312285A (en)	2024-06-01	L-BHDU drugs and treatment methods for viral infections
HK40106970A (zh)	2024-09-27	IFN-λ MRNA治疗病毒感染的用途
GB202006160D0 (en)	2020-06-10	Treatment of viral infections
GB202004998D0 (en)	2020-05-20	Treatment of viral infections
GB202003232D0 (en)	2020-04-22	Treatment of viral infections
GB202312669D0 (en)	2023-10-04	Treatment of viral infections
HK40087038A (en)	2023-09-01	Methods of treating viral infections
ZA202005856B (en)	2021-10-27	Treatment of infections
HK40109846A (zh)	2024-12-13	减少papd5和papd7 mrna的核酸分子用於治疗乙型肝炎感染
HK40096728A (zh)	2024-02-23	用於治疗病毒感染的化合物和方法
HK40083678A (en)	2023-06-30	Treatment of viral infections